Every 10-Q that Rein Therapeutics, Inc. (RNTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNTX filings page.
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on fibrotic diseases and reported results for the three and six months ended June 30, 2026. The company’s lead candidate LTI-03 for idiopathic pulmonary fibrosis is in the Phase 2 RENEW trial, a multi-center randomized, double-blind, placebo-controlled study targeting about 120 patients, with interim data anticipated in the fourth quarter of 2026. Development of LTI-01 remains paused indefinitely to prioritize LTI-03.
The company generated no revenue and recorded a net loss of $6.4 million for the quarter and $12.2 million for the first half of 2026, similar to 2025. Operating expenses for the first half were $11.3 million, primarily research and development. As of June 30, 2026, cash, cash equivalents and investments totaled $43.6 million, and total assets were $66.0 million.
In May 2026, Rein completed an underwritten common stock offering of 57.5 million shares at $1.00 per share, raising gross proceeds of $57.5 million and net proceeds of approximately $53.1 million. Management states that available cash, cash equivalents and investments are expected to fund planned operations, including completion of the Phase 2 RENEW trial, into the first quarter of 2028. The company has an accumulated deficit of $413.5 million and continues to expect operating losses for the foreseeable future.
Rein Therapeutics, Inc. reported a net loss of $5.8 million for the quarter ended March 31, 2026, similar to the $5.5 million loss a year earlier, as it continues to invest in drug development without product revenue. Research and development expenses were $3.1 million and general and administrative expenses were $2.2 million, reflecting its focus on advancing its lead asset.
The company is developing LTI-03 for idiopathic pulmonary fibrosis and is running the Phase 2 RENEW trial, a global, randomized, placebo-controlled study targeting about 120 patients. It dosed the first patient in March 2026 and expects interim topline data in the fourth quarter of 2026.
Cash and cash equivalents were $4.4 million as of March 31, 2026, but in May 2026 Rein raised gross proceeds of $57.5 million in an underwritten offering of 57.5 million shares at $1.00 per share. Management believes the resulting liquidity should fund operations, including completion of the Phase 2 RENEW trial, into the first quarter of 2028, though the company still has an accumulated deficit of $407.1 million and expects continued operating losses.
Rein Therapeutics (RNTX) filed its Q3 2025 report, highlighting clinical and financing updates alongside continued losses. The FDA lifted the full clinical hold on the Phase 2 RENEW trial of LTI-03 for idiopathic pulmonary fibrosis on October 29, 2025, allowing U.S. enrollment to proceed. The study targets up to 120 patients with initial topline data expected in Q3 2026. The company also received authorization to initiate sites in Germany and Poland and previously had MHRA clearance in the U.K.
Financially, Rein reported a Q3 net loss of $5.581M and a nine‑month net loss of $17.904M. Cash and cash equivalents were $4.048M as of September 30, 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern, estimating runway into December 2025. During 2025, it raised modest funds via warrant exercises and exchanges ($1.679M and $3.101M) and a private placement ($0.5M), established an ATM with limited sales, and received three $1.0M Pre‑Paid Advances from Yorkville (net $0.95M each).
As of November 10, 2025, 26,286,382 common shares were outstanding.